Skip Navigation

Cardiovascular Research 2002 54(1):13-15; doi:10.1016/S0008-6363(02)00250-X
© 2002 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Goldsmith, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldsmith, S. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2002, European Society of Cardiology

Vasopressin antagonists in CHF: ready for clinical trials?

Steven R. Goldsmith*

Cardiology Division, Hennepin County Medical Center, 701 Park Avenue, Minneapolis MN 55415, USA

srg_hcmc@yahoo.com

* Tel.: +1-612-347-2875; fax: +1-612-904-4224

Received 28 January 2002; accepted 28 January 2002

The first 10% of the full text of this article appears below.

See article by Naitoh et al. [7] (pages 51–57) in this issue.

Improving survival in congestive heart failure is currently based on blunting the effects of inappropriately increased adrenergic drive, as well as of increased circulating and tissue levels of angiotensin II and aldosterone [1–5].The sympathetic nervous system and renin–angiotensin system comprise two of the three components of the ‘neurohumoral axis’ originally proposed as links to the fundamental pathophysiology of heart failure in 1984 [6]. The third component of that axis as originally postulated was arginine vasopressin (AVP). Research into the possible role of AVP in heart failure has been hampered until comparatively recently by the absence of appropriate antagonists. Now, however, highly effective antagonists of the V1a and V2 receptors for AVP are available, and at least in preliminary human studies, are safe and well tolerated. The study by . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
S. S. Gottlieb
The neurohormonal paradigm:have we gone too far?
J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1458 - 1459.
[Full Text] [PDF]